Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06696703

Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)

Led by First Affiliated Hospital of Harbin Medical University · Updated on 2024-11-20

200

Participants Needed

1

Research Sites

100 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.

CONDITIONS

Official Title

Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with acute ischemic stroke according to 2018 Chinese guidelines
  • First clinical onset or previous cerebral infarction without severe lasting effects (Premorbid mRS ≤2)
  • Age 18 years or older, any gender
  • Baseline NIH Stroke Scale score between 3 and 25
  • Provided written informed consent by patient or legal representative
Not Eligible

You will not qualify if you...

  • Cerebral hemorrhage or other acute hemorrhagic diseases
  • Allergy or intolerance to injectable Human Urinary Kallidinogenase
  • Use of ACE inhibitor drugs within 5 half-lives before or during the study
  • Stent surgery after AIS onset or planned interventional therapy
  • Pregnancy, lactation, or planned pregnancy
  • Life expectancy less than 3 months or unable to complete the study
  • Unwillingness to be followed up or poor compliance
  • Current participation in other clinical research
  • AIS caused by other conditions such as dissection, vasculitis, pre-thrombotic lesions, or drug abuse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhongling Zhang

Harbin, Heilongjiang, China, 150001

Actively Recruiting

Loading map...

Research Team

Z

Zhongling Zhang

CONTACT

S

shanshan yang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS) | DecenTrialz